Whether a result of altered gut microbiota or a change in expression of FXR, disruptions in the circulating bile acid levels contribute towards negative NAFLD-related outcomes and make for a potentially obvious target in both exercise and drug intervention. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.